REDUCE-IT Legacy Analysis Shows Persistent Cardiovascular Benefits After Treatment Cessation

New data presented at the European Society of Cardiology Congress 2026 indicates that adherent patients continue to experience cardiovascular benefits even after stopping Icosapent Ethyl treatment. The legacy analysis underscores the long-term impact of the therapy on heart health outcomes.

28 Aug, 12:15 — 28 Aug, 12:15

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual23h ago

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients - Taiwan News

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients Taiwan News

Read full article →

PERSPECTA

PERSPECTA

REDUCE-IT Legacy Analysis Shows Persistent Cardiovascular Benefits After Treatment Cessation

Sources

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients - Taiwan News

Related Stories

Dutch Health Agency Warns of Potentially Fatal Trump-Shaped Ecstasy Pills

48-Year-Old Anesthesiologist Found Dead in Greek Hospital On-Call Room

Art World Mourns Yayoi Kusama as Tributes Highlight Her Lasting Creative Legacy

Study Reveals Hidden Arterial Calcification in Young Adults

PERSPECTA